Decreased incidence of gout in diabetic patients using pioglitazone.
Niu, Sheng-Wen; Chang, Kai-Ting; Lin, Hugo You-Hsien; Kuo, I-Ching; Chang, Yu-Han; Chen, Yu-Han; Hung, Chi-Chih; Chiu, Yi-Wen; Hwang, Shang-Jyh.
; 57(1): 92-99, 2018 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-29040733
Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.
Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients.
Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan.
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
Severe hypoglycemia and hip fracture in patients with type 2 diabetes: a nationwide population-based cohort study.
HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis.
Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes.
Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.